Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPMY Astellas Pharma	$9.66 0.0%	$9.57	$8.37 ▼ $13.14	N/A	0.23	198,987 shs	652,149 shs
BGNE BeiGene		$194.32	$148.81 ▼ $248.16	$18.03B	0.57	336,431 shs	331,608 shs
RPRX Royalty Pharma	$35.60 -2.5%	$34.40	$24.05 ▼ $37.69	$20.53B	0.5	3.70 million shs	3.75 million shs
SSDOY Shiseido	$16.33 -1.5%	$16.93	$15.32 ▼ $32.17	$6.63B	0.37	29,215 shs	23,460 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPMY Astellas Pharma	-0.04%	+2.07%	+1.11%	+3.27%	-7.51%
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	+20.79%
RPRX Royalty Pharma	-2.49%	-0.75%	+1.42%	+9.52%	+28.57%
SSDOY Shiseido	-1.54%	-10.77%	-3.77%	-2.16%	-42.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALPMY Astellas Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BGNE BeiGene	1.4687 of 5 stars	3.5	0.0	0.0	0.0	0.6	0.8	0.6
RPRX Royalty Pharma	4.9648 of 5 stars	3.6	4.0	3.3	3.7	3.5	1.7	2.5
SSDOY Shiseido	1.1613 of 5 stars	0.0	3.0	0.8	0.0	1.6	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPMY Astellas Pharma	0.00	N/A	N/A	N/A
BGNE BeiGene	3.00	Buy	$274.20	∞ Upside
RPRX Royalty Pharma	3.25	Buy	$48.33	35.77% Upside
SSDOY Shiseido	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BGNE, ALPMY, SSDOY, and RPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/10/2025	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$51.00 ➝ $54.00
5/16/2025	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$51.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPMY Astellas Pharma	$12.56B	N/A	$1.80 per share	5.37	$5.52 per share	N/A
BGNE BeiGene	$3.32B	0.00	N/A	N/A	$37.10 per share	0.00
RPRX Royalty Pharma	$2.26B	8.84	$4.09 per share	8.70	$17.56 per share	2.03
SSDOY Shiseido	$6.55B	1.00	$1.01 per share	16.13	$10.44 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPMY Astellas Pharma	$334.93M	$0.17	56.80	14.20	N/A	2.65%	16.55%	7.35%	7/29/2025 (Estimated)
BGNE BeiGene	-$881.71M	-$8.24	N/A	N/A	N/A	-25.94%	-25.12%	-14.95%	N/A
RPRX Royalty Pharma	$858.98M	$1.85	19.24	7.33	2.43	48.23%	24.71%	13.87%	8/6/2025 (Estimated)
SSDOY Shiseido	-$68.94M	-$0.07	N/A	19.67	N/A	-0.40%	-0.61%	-0.30%	8/6/2025 (Estimated)

Latest BGNE, ALPMY, SSDOY, and RPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	N/A	RPRX Royalty Pharma	$1.10	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	SSDOY Shiseido	$0.0569	$0.06	+$0.0031	$0.06	$1.72 billion	$1.54 billion
5/8/2025	Q1 2025	RPRX Royalty Pharma	$0.99	$1.06	+$0.07	$0.41	$724.69 million	$839.00 million
4/25/2025	Q4 2025	ALPMY Astellas Pharma	$0.1474	$0.27	+$0.1226	$0.27	$3.02 billion	$3.22 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPMY Astellas Pharma	$0.35	3.62%	N/A	205.88%	N/A
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.88	2.47%	N/A	47.57%	5 Years
SSDOY Shiseido	$0.08	0.49%	N/A	N/A	N/A

Latest BGNE, ALPMY, SSDOY, and RPRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/21/2025	RPRX Royalty Pharma	quarterly	$0.22	2.7%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPMY Astellas Pharma	0.37	1.13	0.85
BGNE BeiGene	0.05	1.93	1.72
RPRX Royalty Pharma	0.68	1.56	1.56
SSDOY Shiseido	0.36	1.20	0.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPMY Astellas Pharma	N/A
BGNE BeiGene	48.55%
RPRX Royalty Pharma	54.35%
SSDOY Shiseido	0.02%

Insider Ownership

Company	Insider Ownership
ALPMY Astellas Pharma	N/A
BGNE BeiGene	7.43%
RPRX Royalty Pharma	18.90%
SSDOY Shiseido	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPMY Astellas Pharma	14,754	N/A	N/A	Not Optionable
BGNE BeiGene	9,000	97.62 million	90.20 million	Optionable
RPRX Royalty Pharma	80	562.24 million	455.98 million	Optionable
SSDOY Shiseido	27,908	399.66 million	N/A	Not Optionable

BGNE, ALPMY, SSDOY, and RPRX Headlines

Recent News About These Companies

Shiseido (OTCMKTS:SSDOY) Shares Down 5.2% - Here's Why

July 10, 2025 | marketbeat.com

Shiseido (OTCMKTS:SSDOY) Shares Gap Up - What's Next?

July 9, 2025 | marketbeat.com

Shiseido (OTCMKTS:SSDOY) Shares Gap Down - Here's Why

July 7, 2025 | marketbeat.com

Shiseido Company Stock Price History - Investing.com

July 4, 2025 | investing.com

Shiseido giving away £90 anti-ageing serum that shrinks 'fine lines' in days

July 1, 2025 | mirror.co.ukM

Shiseido taps AI, online channels and slow ageing trend to stay relevant

June 20, 2025 | straitstimes.comS

Shiseido bottles cosmetics with refillable LiquiForm container to cut plastics

June 19, 2025 | packagingeurope.comP

Shiseido Restructures Executive Leadership in Japan

June 5, 2025 | globalcosmeticsnews.comG

Shiseido unveils Japanese Beauty Showcase at Fukuoka Airport

May 28, 2025 | dfnionline.comD

The key trends shaping a sustainable future for Shiseido Travel Retail

May 22, 2025 | dfnionline.comD

Shiseido unveils travel retail campaign for Ultimune Power Infusing Serum

May 19, 2025 | dfnionline.comD

Shiseido Q1 disappoints as Drunk Elephant drags down sales

May 14, 2025 | cosmeticsbusiness.comC

Shiseido Returns to Profit in Q1 Despite Decline in Sales

May 14, 2025 | globalcosmeticsnews.comG

Shiseido Reports Q1 2025 Earnings Amid Global Challenges

May 12, 2025 | tipranks.com

Shiseido EMEA Chairman Steps Down as Company Opts for Streamlined Leadership

May 12, 2025 | globalcosmeticsnews.comG

China travel retail woes trigger industry reset: L’Oréal cuts, Shiseido merges

May 1, 2025 | jingdaily.comJ

Interview: Shiseido Travel Retail Japan powers ahead as new Ultimune line gets off to a flier

April 29, 2025 | moodiedavittreport.comM

2024 Top 100: Shiseido Sees Stable Sales, Plummeting Operating Profit

April 18, 2025 | msn.com

Shiseido Americas announces Interim CEO as Ron Gee resigns

April 17, 2025 | globalcosmeticsnews.comG

Shiseido Americas CEO Ron Gee departs amid sales slowdown

April 16, 2025 | cosmeticsbusiness.comC

Shiseido unveils mineral sun screen development

April 16, 2025 | globalcosmeticsnews.comG

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGNE, ALPMY, SSDOY, and RPRX Company Descriptions

Astellas Pharma OTCMKTS:ALPMY

$9.66 0.00 (-0.04%)

As of 07/16/2025 03:59 PM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Royalty Pharma NASDAQ:RPRX

$35.60 -0.91 (-2.49%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$35.49 -0.11 (-0.31%)

As of 07:01 AM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Shiseido OTCMKTS:SSDOY

$16.33 -0.26 (-1.54%)

As of 07/16/2025 03:59 PM Eastern

Shiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; and skincare and makeup products. It also engages in the restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. Further, it offers childcare facilities. The company sells its products through department, specialized cosmetic, drug, and general merchandise stores. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time